MA38391A1 - Dérivés de pyridinyl et triazolone pyridinyl de fusion - Google Patents

Dérivés de pyridinyl et triazolone pyridinyl de fusion

Info

Publication number
MA38391A1
MA38391A1 MA38391A MA38391A MA38391A1 MA 38391 A1 MA38391 A1 MA 38391A1 MA 38391 A MA38391 A MA 38391A MA 38391 A MA38391 A MA 38391A MA 38391 A1 MA38391 A1 MA 38391A1
Authority
MA
Morocco
Prior art keywords
pyridinyl
compounds
formula
triazolone
fusion
Prior art date
Application number
MA38391A
Other languages
English (en)
Other versions
MA38391B1 (fr
Inventor
John David Lawson
Mark Sabat
Nicholas Scorah
Christopher Smith
Phong H Vu
Haixia Wang
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Publication of MA38391A1 publication Critical patent/MA38391A1/fr
Publication of MA38391B1 publication Critical patent/MA38391B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

L'invention concerne des composés de formule 1 ou des sels pharmaceutiquement acceptables de ceux-ci, dans la formule, r1, r2, r3, et r4 sont tels que définis dans la description. Cette invention concerne également des matières et des procédés permettant de préparer les composés de formule 1, des compositions pharmaceutiques contenant ces composés, ainsi que leur utilisation pour traiter des réactions d'hypersensibilité de type i, des maladies auto-immunes, des troubles inflammatoires, le cancer, des troubles proliférants bénins, et d'autres états associés à la tyrosine kinase de bruton (btk).
MA38391A 2013-03-11 2014-03-10 Dérivés de pyridinyl et triazolone pyridinyl de fusion MA38391B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361776445P 2013-03-11 2013-03-11
PCT/US2014/022801 WO2014164558A1 (fr) 2013-03-11 2014-03-10 Dérivés de pyridinyl et triazolone pyridinyl de fusion

Publications (2)

Publication Number Publication Date
MA38391A1 true MA38391A1 (fr) 2018-01-31
MA38391B1 MA38391B1 (fr) 2018-09-28

Family

ID=50543655

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38391A MA38391B1 (fr) 2013-03-11 2014-03-10 Dérivés de pyridinyl et triazolone pyridinyl de fusion

Country Status (43)

Country Link
US (4) US9402841B2 (fr)
EP (2) EP3235814B1 (fr)
JP (2) JP6271700B2 (fr)
KR (1) KR102300612B1 (fr)
CN (1) CN105121427B (fr)
AP (1) AP2015008646A0 (fr)
AR (1) AR095198A1 (fr)
AU (1) AU2014249248B2 (fr)
BR (1) BR112015020264B1 (fr)
CA (1) CA2899948C (fr)
CL (1) CL2015002370A1 (fr)
CR (1) CR20150470A (fr)
CY (1) CY1119356T1 (fr)
DK (1) DK2970202T3 (fr)
DO (1) DOP2015000184A (fr)
EA (1) EA028584B1 (fr)
EC (1) ECSP15042779A (fr)
ES (2) ES2714166T3 (fr)
GE (1) GEP201706778B (fr)
HK (1) HK1245256B (fr)
HR (1) HRP20170622T1 (fr)
HU (1) HUE032720T2 (fr)
IL (1) IL240353B (fr)
JO (1) JO3377B1 (fr)
LT (1) LT2970202T (fr)
MA (1) MA38391B1 (fr)
ME (1) ME02693B (fr)
MX (1) MX364527B (fr)
MY (1) MY183927A (fr)
PE (1) PE20151889A1 (fr)
PH (1) PH12015502046B1 (fr)
PL (1) PL2970202T3 (fr)
PT (1) PT2970202T (fr)
RS (1) RS55879B1 (fr)
SG (1) SG11201506112QA (fr)
SI (1) SI2970202T1 (fr)
SM (1) SMT201700218T1 (fr)
TN (1) TN2015000342A1 (fr)
TW (1) TWI637950B (fr)
UA (1) UA114944C2 (fr)
UY (1) UY35376A (fr)
WO (1) WO2014164558A1 (fr)
ZA (1) ZA201505996B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9266895B2 (en) 2012-09-10 2016-02-23 Principia Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidines as kinase inhibitors
JO3377B1 (ar) * 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co مشتقات بيريدينيل وبيريدينيل مندمج
EP4681737A3 (fr) 2014-02-21 2026-03-11 Principia Biopharma Inc. Sels et forme solide d'un inhibiteur de btk
CN104447530A (zh) * 2014-12-11 2015-03-25 苏州欧凯医药技术有限公司 4-甲基-2,6-二羧基吡啶的制备方法
US10485797B2 (en) * 2014-12-18 2019-11-26 Principia Biopharma Inc. Treatment of pemphigus
TW201718572A (zh) 2015-06-24 2017-06-01 普林斯匹亞生物製藥公司 酪胺酸激酶抑制劑
EA039213B1 (ru) * 2015-12-24 2021-12-17 Такеда Фармасьютикал Компани Лимитед Сокристалл, способ его получения и лекарственное средство, содержащее сокристалл
DK3402503T3 (da) * 2016-01-13 2020-12-21 Acerta Pharma Bv Terapeutiske kombinationer af et antifolat og en btk-hæmmer
CN109071496B (zh) * 2016-03-31 2021-07-30 武田药品有限公司 异喹啉基三唑酮复合物
IL293621B2 (en) 2016-06-29 2023-09-01 Principia Biopharma Inc Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[4,3-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4 -Methyl-4-[4-(oxane-3-yl)piperazine-1-yl)penta-2-ananitrile
US12168012B2 (en) 2018-07-25 2024-12-17 Novartis Ag NLRP3 inflammasome inhibitors
EP3942045A1 (fr) 2019-03-21 2022-01-26 Onxeo Molécule dbait associée à un inhibiteur de kinase pour le traitement du cancer
AU2020253853A1 (en) * 2019-04-02 2021-11-11 Yonsei University, University - Industry Foundation (UIF) Novel compound and method for preventing or treating of respiratory disease comprising the same as an active ingredient
UY38687A (es) 2019-05-17 2023-05-15 Novartis Ag Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso
JP7795454B2 (ja) 2019-10-14 2026-01-07 プリンシピア バイオファーマ インコーポレイテッド （ｒ）－２－［３－［４－アミノ－３－（２－フルオロ－４－フェノキシ－フェニル）ピラゾロ［３，４－ｄ］ピリミジン－１－イル］ピペリジン－１－カルボニル］－４－メチル－４－［４－（オキセタン－３－イル）ピペラジン－１－イル］ペンタ－２－エンニトリルを投与することにより免疫性血小板減少症を治療する方法
EP4054579A1 (fr) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Méthodes pour le traitement de cancers qui ont acquis une résistance aux inhibiteurs de kinase
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
AU2021209884A1 (en) 2020-01-22 2022-09-15 Principia Biopharma Inc. Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
CN116157404B (zh) 2020-08-14 2025-10-14 诺华股份有限公司 杂芳基取代的螺哌啶基衍生物及其药物用途
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3
WO2025116652A1 (fr) * 2023-11-30 2025-06-05 주식회사 지엔티파마 Composition et méthode de traitement de maladies auto-immunes

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
US5733849A (en) * 1996-03-15 1998-03-31 Rohm And Haas Company Halopyridyl triazolinone herbicides and herbicidal use thereof
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
WO1999054286A2 (fr) 1998-04-17 1999-10-28 Parker Hughes Institute Inhibiteurs btk et leurs procedes d'identification et d'utilisation
ES2266258T3 (es) * 2000-09-15 2007-03-01 Vertex Pharmaceuticals Incorporated Compuestos de pirazol utiles como inhibidores de proteina cinasas.
AU3113902A (en) 2000-12-21 2002-07-01 Bristol Myers Squibb Co Thiazolyl inhibitors of tec family tyrosine kinases
US7572809B2 (en) * 2005-12-19 2009-08-11 Hoffmann-La Roche Inc. Isoquinoline aminopyrazole derivatives
BRPI0621027A2 (pt) 2006-01-13 2011-11-29 Pharmacyclics Inc composto, composição farmacêutica
CA2653329C (fr) * 2006-05-25 2018-01-16 Synta Pharmaceuticals Corp. Composes de triazole modulant l'activite de hsp90
KR101066306B1 (ko) 2006-06-20 2011-09-20 에프. 호프만-라 로슈 아게 테트랄린 및 인데인 유도체 및 이들의 용도
AR063946A1 (es) 2006-09-11 2009-03-04 Cgi Pharmaceuticals Inc Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
PL2526933T3 (pl) 2006-09-22 2015-08-31 Pharmacyclics Llc Inhibitory kinazy tyrozynowej Brutona
SG10201508035TA (en) 2007-03-28 2015-10-29 Pharmacyclics Inc Inhibitors of bruton's tyrosine kinase
CN101952283B (zh) 2007-12-14 2013-04-17 霍夫曼-拉罗奇有限公司 咪唑并[1，2-a]吡啶和咪唑并[1，2-b]哒嗪衍生物
DK2242749T3 (da) 2008-02-05 2013-06-17 Hoffmann La Roche Nye pyridinoner og pyridazinoner
EP2297142B1 (fr) 2008-06-24 2015-10-14 F. Hoffmann-La Roche AG Nouvelles pyridine-2-ones et pyridazine-3-ones substituées
CA2728683C (fr) 2008-07-02 2017-05-02 F.Hoffmann-La Roche Ag Nouvelles phenylpyrazinones en tant qu'inhibiteurs de kinases
CA2726460C (fr) 2008-07-15 2017-02-21 F. Hoffmann-La Roche Ag Nouvelles phenyl-imidazopyridines et pyridazines
US8598174B2 (en) 2008-11-12 2013-12-03 Genetech, Inc. Pyridazinones, method of making, and method of use thereof
WO2010068810A2 (fr) 2008-12-10 2010-06-17 Cgi Pharmaceuticals, Inc. Amides substitués, et leurs procédés de production et d'utilisation
WO2010068788A1 (fr) 2008-12-10 2010-06-17 Cgi Pharmaceuticals, Inc. Amides hétérocycliques en tant qu'inhibiteurs de la btk
JP2013526546A (ja) 2010-05-13 2013-06-24 アムジエン・インコーポレーテツド Ｐｄｅ１０阻害剤としてのヘテロアリ−ルオキシヘテロシクリル化合物
WO2011153553A2 (fr) 2010-06-04 2011-12-08 The Regents Of The University Of California Méthodes et compositions pour l'inhibition de kinases
AR083267A1 (es) * 2010-10-04 2013-02-13 Novartis Ag Combinaciones farmaceuticas
US8552200B2 (en) 2010-10-20 2013-10-08 Gruenenthal Gmbh Substituted 6-amino-nicotinamides as KCNQ2/3 modulators
EP2637816A4 (fr) 2010-11-10 2017-07-26 Stc.Unm Synthèse par réduction/expansion en aérosol (a-res) pour particules de métal à valence zéro
JO3377B1 (ar) * 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co مشتقات بيريدينيل وبيريدينيل مندمج

Also Published As

Publication number Publication date
SMT201700218T1 (it) 2017-07-18
AP2015008646A0 (en) 2015-08-31
EP2970202A1 (fr) 2016-01-20
US10307414B2 (en) 2019-06-04
SG11201506112QA (en) 2015-09-29
US9801872B2 (en) 2017-10-31
PH12015502046B1 (en) 2019-01-23
EP3235814A1 (fr) 2017-10-25
JP2018076357A (ja) 2018-05-17
CL2015002370A1 (es) 2016-03-11
HRP20170622T1 (hr) 2017-06-30
GEP201706778B (en) 2017-11-27
US20160310483A1 (en) 2016-10-27
RS55879B1 (sr) 2017-08-31
ECSP15042779A (es) 2017-08-31
PH12015502046A1 (en) 2016-01-18
WO2014164558A1 (fr) 2014-10-09
TW201522328A (zh) 2015-06-16
TN2015000342A1 (en) 2017-01-03
ME02693B (fr) 2017-10-20
PT2970202T (pt) 2017-05-03
US20140256734A1 (en) 2014-09-11
MA38391B1 (fr) 2018-09-28
PL2970202T3 (pl) 2017-08-31
EP2970202B1 (fr) 2017-02-01
US20190224190A1 (en) 2019-07-25
HK1220183A1 (en) 2017-04-28
AR095198A1 (es) 2015-09-30
CN105121427A (zh) 2015-12-02
JP6271700B2 (ja) 2018-01-31
ZA201505996B (en) 2016-11-30
CA2899948C (fr) 2021-11-16
ES2714166T3 (es) 2019-05-27
EA201591686A1 (ru) 2015-12-30
BR112015020264B1 (pt) 2021-03-02
AU2014249248B2 (en) 2017-08-17
KR102300612B1 (ko) 2021-09-09
MY183927A (en) 2021-03-17
EA028584B1 (ru) 2017-12-29
MX364527B (es) 2019-04-30
UY35376A (es) 2014-10-31
LT2970202T (lt) 2017-06-12
CN105121427B (zh) 2018-04-10
CA2899948A1 (fr) 2014-10-09
CR20150470A (es) 2016-01-11
JO3377B1 (ar) 2019-03-13
PE20151889A1 (es) 2015-12-26
HUE032720T2 (en) 2017-10-30
DOP2015000184A (es) 2015-11-30
EP3235814B1 (fr) 2018-12-12
NZ710852A (en) 2020-12-18
HK1245256B (en) 2019-09-27
US20180015083A1 (en) 2018-01-18
KR20150126687A (ko) 2015-11-12
MX2015011533A (es) 2016-02-03
JP2016512515A (ja) 2016-04-28
US9402841B2 (en) 2016-08-02
BR112015020264A2 (pt) 2017-07-18
DK2970202T3 (en) 2017-05-08
AU2014249248A1 (en) 2015-08-20
IL240353A0 (en) 2015-09-24
UA114944C2 (uk) 2017-08-28
SI2970202T1 (sl) 2017-07-31
JP6462842B2 (ja) 2019-01-30
ES2624439T3 (es) 2017-07-14
CY1119356T1 (el) 2018-02-14
IL240353B (en) 2018-11-29
TWI637950B (zh) 2018-10-11

Similar Documents

Publication Publication Date Title
MA38391B1 (fr) Dérivés de pyridinyl et triazolone pyridinyl de fusion
MA47079A (fr) Composés amino-triazolopyidines et leur utilisation pour traiter le cancer
MA40111B1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
TN2016000188A1 (fr) Derives de purines 2,6-substitues et leur utilisation dans le traitement de troubles proliferatifs.
MA35348B1 (fr) 4-imidazopyridazin-1-yl-benzamides et 4-imidazotriazin-1-yl-benzamides en tant qu'inhibiteurs de btk
MA39783A (fr) Dérivés de quinoxaline utiles en tant que modulateurs de la fgfr kinase
MA54653B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
TN2014000420A1 (fr) Derives d'indole et d'indazole qui activent la mpk
MA38138A1 (fr) Dérivés inédits de quinolone
WO2019035864A8 (fr) Activateurs de la pyruvate kinase destinés à être utilisés dans le traitement de troubles sanguins
MA38380A1 (fr) Inhibiteurs quinazoline de l'activation des formes mutantes du récepteur de croissance épidermique (egfr)
MA41179A (fr) Composés inhibiteurs de parg
MA40225A (fr) Composés dihydroisoquinolinone substitués
TN2014000537A1 (fr) 4-(amino-substitue) – 7h-pyrrolo [2, 3-d] pyrimidines nouvelles servant d'inhibiteurs de lrrk2
MA37400B1 (fr) Composés hétérocyclyle en tant qu'inhibiteurs de mek
MA31683B1 (fr) Composes et procedes pour moduler fxr
MA35826B1 (fr) Triazolopyridines substituées et leur utilisation à titre d'inhibiteurs de ttk
MA37831B1 (fr) Dérivés d'azaindole agissant comme inhibiteur de pi3k
MA38260A1 (fr) Nouveaux dérivés de cyclohexyl et quinuclidinyl carbamate ayant une activité d'agoniste adrénergique beta2 et une activité d'antagoniste muscarinique m3
MA33533B1 (fr) Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles
CA2878796C (fr) Derives de pyridinone comme inhibiteurs de la transglutaminase tissulaire
MA46229B1 (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
MA37742B1 (fr) Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments
MA46268A (fr) Dérivés de 5-[2-(pyridin-2-ylamino)-1,3-thiazol-5-yl]-2,3-dihydro-1h-isoindol-1-one et leur utilisation en tant qu'inhibiteurs doubles de phosphatidylinositol 3-kinase delta & gamma
MA44965B1 (fr) Dérivés de pyridinyle, compositions pharmaceutiques et utilisations de ceux-ci en tant qu'inhibiteurs d'aoc3